Laboratory trials on oxamniquine (UK-4271), a candidate schistosomicide.
D000284:Administration, Oral; D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use*; D004195:Disease Models, Animal; D000882:Haplorhini; D007273:Injections, Intramuscular; D008099:Liver / Q000187:drug effects; D008111:Liver Function Tests; D051379:Mice; D009574:Nitro Compounds / Q000009:adverse effects / Q000627:therapeutic use; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use*; D012552:Schistosomiasis / Q000188:drug therapy*; D012556:Schistosomicides / Q000009:adverse effects / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced
D000871:Anthelmintics; D009574:Nitro Compounds; D011437:Propylamines; D011804:Quinolines; D012556:Schistosomicides